drugset / Trial / NCT03471351
Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
NaSingle-groupOpen-labelTreatment
Summary
To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) for Tenalisib in combination with Pembrolizumab in patients with cHL.
Timeline
- Start
- 2018-07-18
- Primary completion
- 2019-02-13
- Completion
- 2019-02-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Tenalisib | Small molecule | — | Oral |